Literature DB >> 20207023

Therapy for persistent HIV.

Kara S Keedy1, David M Margolis.   

Abstract

Given the scope of the human immunodeficiency virus (HIV) pandemic, millions of people will need of chronic antiretroviral therapy (ART) for decades into the future. It is hoped that progress in prevention of HIV infection can be made, but there have been few successes in this effort thus far. ART also presents formidable problems. Therefore, research must continue on improvements in prevention and treatment, but future HIV research should now also seek to develop temporally contained therapies capable of eradicating HIV infection. This review will explore what is known about the mechanisms that restrain HIV expression and result in persistent, latent proviral infection, and what these mechanisms tell us about potential approaches towards eradication of HIV infection. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20207023      PMCID: PMC2862871          DOI: 10.1016/j.tips.2010.02.001

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  47 in total

1.  Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing.

Authors:  Céline Marban; Stella Suzanne; Franck Dequiedt; Stéphane de Walque; Laetitia Redel; Carine Van Lint; Dominique Aunis; Olivier Rohr
Journal:  EMBO J       Date:  2007-01-24       Impact factor: 11.598

2.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

3.  HIV-1 infection and pathogenesis in a novel humanized mouse model.

Authors:  Liguo Zhang; Grigoriy I Kovalev; Lishan Su
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 4.  Chromatin-associated regulation of HIV-1 transcription: implications for the development of therapeutic strategies.

Authors:  Vincent Quivy; Stephane De Walque; Carine Van Lint
Journal:  Subcell Biochem       Date:  2007

5.  Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.

Authors:  Dan Peer; Eun Jeong Park; Yoshiyuki Morishita; Christopher V Carman; Motomu Shimaoka
Journal:  Science       Date:  2008-02-01       Impact factor: 47.728

6.  Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.

Authors:  John M Murray; Sean Emery; Anthony D Kelleher; Matthew Law; Joshua Chen; Daria J Hazuda; Bach-Yen T Nguyen; Hedy Teppler; David A Cooper
Journal:  AIDS       Date:  2007-11-12       Impact factor: 4.177

7.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

8.  Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes.

Authors:  Jialing Huang; Fengxiang Wang; Elias Argyris; Keyang Chen; Zhihui Liang; Heng Tian; Wenlin Huang; Kathleen Squires; Gwen Verlinghieri; Hui Zhang
Journal:  Nat Med       Date:  2007-09-30       Impact factor: 53.440

9.  Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells.

Authors:  Kara G Lassen; Kasra X Ramyar; Justin R Bailey; Yan Zhou; Robert F Siliciano
Journal:  PLoS Pathog       Date:  2006-07       Impact factor: 6.823

10.  Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1.

Authors:  Zhifeng Sun; Paul W Denton; Jacob D Estes; Florence A Othieno; Bangdong L Wei; Anja K Wege; Michael W Melkus; Angela Padgett-Thomas; Mary Zupancic; Ashley T Haase; J Victor Garcia
Journal:  J Exp Med       Date:  2007-03-26       Impact factor: 14.307

View more
  8 in total

Review 1.  New insights into HIV assembly and trafficking.

Authors:  Muthukumar Balasubramaniam; Eric O Freed
Journal:  Physiology (Bethesda)       Date:  2011-08

Review 2.  Eliminating the HIV reservoir.

Authors:  Alain Lafeuillade
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

Review 3.  Anti-viral opportunities during transcriptional activation of latent HIV in the host chromatin.

Authors:  Shiraz Mujtaba; Ming-Ming Zhou
Journal:  Methods       Date:  2010-09-07       Impact factor: 3.608

4.  Isothiocyanates ameliorate the symptom of heart dysfunction and mortality in a murine AIDS model by inhibiting apoptosis in the left ventricle.

Authors:  Jin-Nyoung Ho; Ho-Geun Yoon; Chang-Soo Park; Sunoh Kim; Woojin Jun; Ryowon Choue; Jeongmin Lee
Journal:  J Med Food       Date:  2012-09       Impact factor: 2.786

5.  FIV establishes a latent infection in feline peripheral blood CD4+ T lymphocytes in vivo during the asymptomatic phase of infection.

Authors:  Brian Murphy; Natasha Vapniarsky; Chad Hillman; Diego Castillo; Samantha McDonnel; Peter Moore; Paul A Luciw; Ellen E Sparger
Journal:  Retrovirology       Date:  2012-02-07       Impact factor: 4.602

6.  Transcriptional provirus silencing as a crosstalk of de novo DNA methylation and epigenomic features at the integration site.

Authors:  Filip Senigl; Miroslav Auxt; Jirí Hejnar
Journal:  Nucleic Acids Res       Date:  2012-02-29       Impact factor: 16.971

Review 7.  Feline immunodeficiency virus latency.

Authors:  Samantha J McDonnel; Ellen E Sparger; Brian G Murphy
Journal:  Retrovirology       Date:  2013-07-06       Impact factor: 4.602

8.  Gut immune dysfunction through impaired innate pattern recognition receptor expression and gut microbiota dysbiosis in chronic SIV infection.

Authors:  T W Glavan; C A Gaulke; C Santos Rocha; S Sankaran-Walters; L A Hirao; M Raffatellu; G Jiang; A J Bäumler; L R Goulart; S Dandekar
Journal:  Mucosal Immunol       Date:  2015-09-16       Impact factor: 7.313

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.